• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4592165)   Today's Articles (3243)   Subscriber (49315)
Number Citation Analysis
1
P.98RCT of 2mg bumetanide for hypokalaemic periodic paralysis. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.127] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
2
Urogenital symptoms in mitochondrial disease: overlooked and undertreated. Eur J Neurol 2019;26:1111-1120. [PMID: 30884027 PMCID: PMC6767393 DOI: 10.1111/ene.13952] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2018] [Accepted: 03/11/2019] [Indexed: 11/30/2022]
3
Pilot study to explore the frequency and severity of pain in skeletal muscle channelopathies. Neuromuscul Disord 2018. [DOI: 10.1016/s0960-8966(18)30374-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
4
RCT of bumetanide in hypokalaemic periodic paralysis (HypoPP) using abductor digiti minimi compound muscle action potential (CMAP) as an objective outcome measure. Neuromuscul Disord 2018. [DOI: 10.1016/s0960-8966(18)30370-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
5
RCT of Bumetanide in Hypokalaemic Periodic Paralysis (HypoPP) using abductor digiti minimi compound muscle action potential (CMAP) as an objective outcome measure. Muscle Nerve 2017. [DOI: 10.1002/mus.25769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
6
Cause of death in a cohort of mitochondrial patients. Neuromuscul Disord 2017. [DOI: 10.1016/s0960-8966(17)30272-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
7
Bumetanide in hypokalaemic periodic paralysis: a randomised, double-blind, placebo controlled phase II clinical trial with a crossover design. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
8
Evaluating the benefits of community based aerobic training on the physical health and well-being of people with neuromuscular diseases: A pilot study. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.317] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA